TRANSLATE

The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

59th ASH® Annual Meeting and Exposition: abstract submission deadline 2nd August

By Cynthia Umukoro

Share:

Jul 31, 2017


The 59th American Society of Hematology (ASH) Meeting and Exposition will take place in Atlanta, Georgia, USA, from 9th – 12th December 2017. Abstract submission is due to close on Wednesday August 2nd, 11:59 p.m. (Pacific Time); with the call for late-breaking abstract submissions from 20th – 30th October. Registration opened for ASH members on 19th July and will open to non-members on 9th August, 11:00 a.m. Eastern Time; the registration deadline is 1st November. To learn more about the meeting, you can download the preliminary program or visit the official conference website.

The meeting is described by ASH as, “The premier event in malignant and non-malignant hematology”, and will showcase the best scientific research in these fields. The conference will include standard oral sessions of the best selected abstracts, poster sessions, as well as ‘scientific spotlight sessions’ and the opportunity to ‘meet the scientist’. Smaller ‘special interest sessions’ have been scheduled targeting both scientists and practicing hematologists, covering topics such as ‘How to Get published in a Peer-Reviewed Journal’ as well as a special education session on ‘New ASH Clinical Practice Guidelines on Venous Thromboembolism (VTE)’, and a networking reception for female hematologists. Such sessions will contribute to an all-round educational experience, with numerous training opportunities available, in addition to the opportunity to meet with leading scientific researchers and clinicians from a global community of more than 25,000 attendees.

The AML Global Portal will be covering key highlights from ASH 2017 including oral sessions, late breaking abstracts, video interviews with key thought leaders and educational sessions, with a focus on the latest AML research that impacts clinical practice.

Your opinion matters

Approximately what proportion of your patients with FLT3-mutations also have NPM1 and DNMT3A co-mutations?